Idogen
Be the first to follow this company
Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection.
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 8.5 % | 8.5 % |
Ranya Usta | 2.7 % | 2.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Idogen has been delisted from First North Growth Market
Idogen har försatts i konkurs
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools